



Vectical® (calcitriol) – Expanded indication

- On July 17, 2020, the [FDA approved](#) Galderma's [Vectical \(calcitriol\)](#), for the topical treatment of mild to moderate plaque psoriasis in adults and pediatric patients 2 years and older.
 - Vectical was previously approved for this indication in adults 18 years and older.
 - The safety and effectiveness of Vectical in patients with known or suspected disorders of calcium metabolism have not been evaluated.
- The use of Vectical in pediatric patients is supported by two adequate and well-controlled 8-week trials and an open label trial in adult patients, and additional data from trials conducted in pediatric patients 2 to 17 years of age.
 - Data from 63 patients ages 2 to 12 years, and 42 patients ages 13 to 17 years showed no significant effects on indices of calcium metabolism.
 - The systemic exposure of calcitriol in the pediatric patients was generally comparable to the endogenous levels observed at baseline. No new safety signals were identified in subjects 2 to 17 years.
- The recommended administration of Vectical ointment for the treatment of pediatric patients is an application to affected areas twice daily (morning and evening). In pediatric patients 2 to 6 years of age, the maximum weekly dose should not exceed 100 grams. In pediatric patients 7 years of age and older, the maximum weekly dose should not exceed 200 grams.
 - Refer to the Vectical drug label for dosing recommendations in adults.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.